ES2149451T3 - Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido. - Google Patents

Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido.

Info

Publication number
ES2149451T3
ES2149451T3 ES96903340T ES96903340T ES2149451T3 ES 2149451 T3 ES2149451 T3 ES 2149451T3 ES 96903340 T ES96903340 T ES 96903340T ES 96903340 T ES96903340 T ES 96903340T ES 2149451 T3 ES2149451 T3 ES 2149451T3
Authority
ES
Spain
Prior art keywords
alpha
hexahidrobenz
isoindol
adrenergic antagonists
substituted tricyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96903340T
Other languages
English (en)
Inventor
Michael D Meyer
Robert J Altenbach
Fatima Z Basha
William A Carroll
Irene Drizin
James F Kerwin Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2149451T3 publication Critical patent/ES2149451T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE W ES UN ANILLO TRICICLICO HETEROCICLICO, EL CUAL ES UN ANTAGONISTA {AL}-1 ADRENERGICO Y ES UTIL EN EL TRATAMIENTO DE BPH; TAMBIEN SE REVELAN LAS COMPOSICIONES {AL}-1 ANTAGONISTAS Y UN METODO PARA ANTAGONIZAR A LOS RECEPTORES {AL}-1 Y TRATAR EL BPH.
ES96903340T 1995-01-27 1996-01-11 Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido. Expired - Lifetime ES2149451T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37941495A 1995-01-27 1995-01-27
US08/463,528 US5597823A (en) 1995-01-27 1995-06-05 Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists

Publications (1)

Publication Number Publication Date
ES2149451T3 true ES2149451T3 (es) 2000-11-01

Family

ID=27008615

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96903340T Expired - Lifetime ES2149451T3 (es) 1995-01-27 1996-01-11 Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido.

Country Status (15)

Country Link
US (1) US5597823A (es)
EP (1) EP0808318B1 (es)
JP (1) JP2001504797A (es)
KR (1) KR19980701700A (es)
AT (1) ATE194141T1 (es)
AU (1) AU705283B2 (es)
CA (1) CA2211212A1 (es)
DE (1) DE69609051T2 (es)
DK (1) DK0808318T3 (es)
ES (1) ES2149451T3 (es)
GR (1) GR3034485T3 (es)
IL (1) IL116405A (es)
MX (1) MX9705674A (es)
PT (1) PT808318E (es)
WO (1) WO1996022992A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AR008395A1 (es) * 1996-07-09 2000-01-19 Astra Pharma Prod Compuesto derivado de pirimidina, composicion farmaceutica que lo comprende, procedimiento para prepararlo, y compuesto intermediario util parallevar a cabo dicho procedimiento.
US5891882A (en) * 1996-12-06 1999-04-06 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine α-1 adenergic compounds
EP1023068A4 (en) * 1997-06-18 2001-05-16 Merck & Co Inc ALPHA 1a ADRENORE RECEPTOR ANTAGONISTS
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
AU3011299A (en) * 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
HU227475B1 (en) 1998-08-20 2011-07-28 Toyama Chemical Co Ltd Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing them
CA2340250A1 (en) * 1998-08-20 2000-03-02 Kelley L. Ford Process for preparing regiospecific substituted pyrazine isomers
CZ20012350A3 (cs) * 1998-12-24 2001-09-12 Aventis Pharmaceuticals Products Inc. Substituované (aminoiminomethyl nebo aminomethyl) benzoheteroarylové sloučeniny
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
JP2005104838A (ja) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7524853B2 (en) * 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
RU2409581C2 (ru) * 2004-12-13 2011-01-20 Зольвай Фармасьютиклз Гмбх НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ
CN101087793B (zh) * 2004-12-13 2011-09-07 索尔瓦药物有限公司 作为17β-羟基类固醇脱氢酶抑制剂的新的取代的噻吩嘧啶酮衍生物
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
CN101248060B (zh) 2005-06-23 2014-09-10 阵列生物制药公司 用于制备苯并咪唑化合物的方法
WO2007056184A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
JP5041403B2 (ja) * 2007-02-02 2012-10-03 国立大学法人北海道大学 カフェイン類縁体
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
HK1217325A1 (zh) 2012-12-20 2017-01-06 奥尔德拉医疗公司 迫位原醇
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
HK1217490A1 (zh) 2013-01-25 2017-01-13 Aldeyra Therapeutics, Inc. 黃斑變性治療中的新穎捕獲劑
CN108135907A (zh) 2015-08-21 2018-06-08 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN112079832A (zh) * 2020-10-30 2020-12-15 黑龙江中医药大学 一种治疗子宫肌瘤的药物及其制备方法
CN114957090B (zh) * 2021-12-31 2023-09-19 淮阴师范学院 稠合异吲哚衍生物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
GB9123857D0 (en) * 1991-11-09 1992-01-02 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
DE69609051D1 (de) 2000-08-03
KR19980701700A (ko) 1998-06-25
CA2211212A1 (en) 1996-08-01
IL116405A (en) 2001-09-13
DE69609051T2 (de) 2001-03-22
EP0808318A1 (en) 1997-11-26
AU4745796A (en) 1996-08-14
ATE194141T1 (de) 2000-07-15
EP0808318B1 (en) 2000-06-28
GR3034485T3 (en) 2000-12-29
AU705283B2 (en) 1999-05-20
WO1996022992A1 (en) 1996-08-01
IL116405A0 (en) 1996-03-31
PT808318E (pt) 2000-12-29
JP2001504797A (ja) 2001-04-10
MX9705674A (es) 1997-10-31
DK0808318T3 (da) 2000-10-16
US5597823A (en) 1997-01-28

Similar Documents

Publication Publication Date Title
DE69609051D1 (de) Tricyclische substituierte hexahydrobenz[e]isoindol alpha-1-adrenergische antagonisten
ES2159721T3 (es) Antagonistas alfa-1-adrenergicos biciclicos sustituidos de hexahidrobenz(e)isoindol.
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
RU2012110522A (ru) Гипотензивная комбинация валсартана и блокатора кальциевых каналов
DK0565634T3 (da) Angiotensin-II-receptorblokkersammensætninger
ATE204857T1 (de) Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
DE69422303D1 (de) Neue 4-piperidinyl substituierte lactame als neukokinin 2 rezeptor antagonisten zur behandlung von asthma
DE69734321D1 (de) Non-peptidische vasopressin via antagonisten
TR199901883T2 (xx) Benzopiranopirol ve benzopiranopiridin alfa-1 adrenerjik bile�ikleri.
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
DE69819166D1 (de) 8-substituierte-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepin derivate als ampa/kainate-rezeptor-hemmer
MX9708557A (es) Nuevo uso farmacologico de los antagonistas del receptor aii.
PT804186E (pt) Compostos alcaloides diterpenicos de indole
ES2149984T3 (es) Derivados imidazolilalquilos de imidazol(5,1-c)(1,4)benzoxazin-1-ona y su utilizacion como agentes terapeuticos.
EP2140862A3 (en) Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
BR9713682A (pt) Compostos alfa - 1 adrenergicos de benzopiranopirrol e benzopiranopiridina
NO981188L (no) 5-HT3-reseptorantagonister for dyskinesi
DE69903930D1 (de) N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen
ES2101646A1 (es) Nuevo compuesto derivado del cromeno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 808318

Country of ref document: ES